By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



The John Hancock Tower, 54th Floor
200 Clarendon Street
Boston  Massachusetts  02116  U.S.A.
Phone: 617-425-9200 Fax: 617-425-9201



Company News
Rhythm Announces The New England Journal of Medicine Publication Of Setmelanotide Phase 2 Data For Treatment Of POMC Deficiency Obesity 7/21/2016 6:31:10 AM
Rhythm Wins FDA Breakthrough Tag for Setmelanotide for the Treatment Of POMC Deficiency Obesity 1/7/2016 7:41:10 AM
Rhythm Receives Orphan Drug Designation For Setmelanotide For The Treatment Of Prader-Willi Syndrome 1/7/2016 7:36:39 AM
Rhythm And Camurus Announce License Agreement For Extended Release Fluidcrystal Setmelanotide 1/5/2016 6:38:11 AM
Rhythm Appoints David Meeker, MD, And David Mcgirr To Board Of Directors 12/16/2015 8:27:11 AM
Rhythm Presents Cardiovascular Safety Data From Phase 1b/2a Clinical Trials Of Setmelanotide In Obesity 11/6/2015 10:32:52 AM
Rhythm Presents Positive Data From Phase 1b Study Of Setmelanotide For The Treatment Of Genetic Obesity 11/6/2015 7:00:11 AM
FDA Office Of Orphan Products Development Awards Rhythm $1 Million Grant To Support Phase 2 Study Of Setmelanotide In Prader-Willi Syndrome 9/24/2015 10:17:41 AM
Rhythm Initiates Two Phase 2 Clinical Trials Of Setmelanotide (RM-493) In Rare Genetic Disorders Of Obesity Caused By MC4 Pathway Deficiencies 6/4/2015 6:25:50 AM
Rhythm Initiates Phase 2b Clinical Trial Of Relamorelin For Diabetic Gastroparesis 4/8/2015 6:14:13 AM